Skip to main content
Top
Published in: Pituitary 4/2012

01-12-2012

Ovarian tumor-derived ectopic hyperprolactinemia

Authors: Autumn F. Elms, S. J. Carlan, Amy E. Rich, Lizardo Cerezo

Published in: Pituitary | Issue 4/2012

Login to get access

Abstract

To describe extreme hyperprolactinemia originating from a pituitary adenoma in the wall of an ovarian dermoid. This is a description of an unusual case and a review of ectopic prolactin production. Ectopic production of prolactin is a rare condition that has been reported in isolated organ system pathology including ovaries. An ovarian dermoid is a benign neoplasm that has the potential for active unregulated endocrine function. Hyperprolactinemia can result from functioning lactotrophs found in ovarian dermoids and can lead to clinical sequelae. Definitive treatment of the condition requires surgical removal of the functioning endocrine tissue. Extreme hyperprolactinemia caused by a pituitary tumor located within a dermoid has not been reported before. We present a case of profound hyperprolactinemia originating from a pituitary adenoma found in the wall of an ovarian dermoid and give a broad overview of the condition and literature. Ectopic prolactin production should always be considered in symptomatic patients found to have elevated serum levels and no findings on brain imaging.
Literature
1.
go back to reference Zalel Y, Piura B, Elchalal U et al (1996) Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet 55:1–10PubMedCrossRef Zalel Y, Piura B, Elchalal U et al (1996) Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet 55:1–10PubMedCrossRef
2.
go back to reference Killackey MA, Neuwirth RS (1988) Evaluation and management of the pelvic mass: a review of 540 cases. Obstet Gynecol 71:319–322PubMed Killackey MA, Neuwirth RS (1988) Evaluation and management of the pelvic mass: a review of 540 cases. Obstet Gynecol 71:319–322PubMed
3.
go back to reference Melmed S, Casanueva FF, Hoffman AR et al (2011) Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMedCrossRef Melmed S, Casanueva FF, Hoffman AR et al (2011) Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMedCrossRef
4.
6.
go back to reference Hsu CT, Yu MH et al (1992) Ectopic production of prolactin in uterine cervical carcinoma. Gynecol Oncol 44:166–171PubMedCrossRef Hsu CT, Yu MH et al (1992) Ectopic production of prolactin in uterine cervical carcinoma. Gynecol Oncol 44:166–171PubMedCrossRef
7.
go back to reference Akhtar M, Young I, Brody H (1975) Anterior pituitary component in benign cystic ovarian teratomas; report of three cases. Am J Clin Path 63:14–19 Akhtar M, Young I, Brody H (1975) Anterior pituitary component in benign cystic ovarian teratomas; report of three cases. Am J Clin Path 63:14–19
8.
go back to reference McKeel DW, Askin FB (1978) Ectopic hypohyseal hormonal cells in benign cystic teratoma of the ovary. Arch Pathol Lab Med 102:122–128PubMed McKeel DW, Askin FB (1978) Ectopic hypohyseal hormonal cells in benign cystic teratoma of the ovary. Arch Pathol Lab Med 102:122–128PubMed
9.
go back to reference Wahba MH (1980) Cure of postpartum hyperprolactinemia galactorrhea–amenorrhea by removal of benign ovarian teratoma. Two case reports. Br J Obstet Gynecol 87:631–633CrossRef Wahba MH (1980) Cure of postpartum hyperprolactinemia galactorrhea–amenorrhea by removal of benign ovarian teratoma. Two case reports. Br J Obstet Gynecol 87:631–633CrossRef
10.
go back to reference Axiotis CA, Lippes HA, Merino MJ et al (1987) Corticotroph cell pituitary adenoma within an ovarian teratoma. A new cause of Cushing’s syndrome. Am J Surg Pathol 11:218–224PubMedCrossRef Axiotis CA, Lippes HA, Merino MJ et al (1987) Corticotroph cell pituitary adenoma within an ovarian teratoma. A new cause of Cushing’s syndrome. Am J Surg Pathol 11:218–224PubMedCrossRef
11.
go back to reference Palmer PE, Bogojavlensky S, Bhan AK et al (1990) Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia. Obstet Gynecol 75:540–542PubMed Palmer PE, Bogojavlensky S, Bhan AK et al (1990) Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia. Obstet Gynecol 75:540–542PubMed
12.
go back to reference Kallenberg GA, Pesce CM, Norman B et al (1990) Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA 263:2472–2474PubMedCrossRef Kallenberg GA, Pesce CM, Norman B et al (1990) Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA 263:2472–2474PubMedCrossRef
13.
go back to reference Papakostas GI, Miller KK, Petersen T et al (2006) Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 67:952–957PubMedCrossRef Papakostas GI, Miller KK, Petersen T et al (2006) Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 67:952–957PubMedCrossRef
Metadata
Title
Ovarian tumor-derived ectopic hyperprolactinemia
Authors
Autumn F. Elms
S. J. Carlan
Amy E. Rich
Lizardo Cerezo
Publication date
01-12-2012
Publisher
Springer US
Published in
Pituitary / Issue 4/2012
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0366-4

Other articles of this Issue 4/2012

Pituitary 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine